Q1 FY 20 Performance Update
Recent Updates - YTD FY 20
United States
Launched 10 products including some complex and
First-to-market Assets like Daptomycin Inj, Carboprost
Inj, Vitamin K Inj, OTC Guaifenesin Pseudoephedrine and
re-launch of Isotretinoin
gCopaxone and g Nuvaring: received Complete Response
Letter from USFDA; preparing for response
India
Growth faster than the
overall market [Dr. Reddy's
growth of 13.0% vs market
growth of 10.4%]
*As per IQVIA MAT June' 2019
Proprietary Products
Canada
Received $ 50 million
as settlement towards
Section 8 damages for
Lenalidomide
Out licenced ZEMBRACE® SYMTOUCH® (Sumatriptan
injection) 3 mg and TOSYMRATM (Sumatriptan nasal spray)
10 mg, for U.S. $ 110.5 million as upfront consideration /
near term milestones, and future sales based royalties.
Successful completion of Phase 2B studies for PPC-06 (XP
- 23829)
8
PROPRIETARYView entire presentation